Tryptamines and Mental Health: Activating the 5-HT Receptor for Therapeutic Potential.
Journal
ACS medicinal chemistry letters
ISSN: 1948-5875
Titre abrégé: ACS Med Chem Lett
Pays: United States
ID NLM: 101521073
Informations de publication
Date de publication:
12 Oct 2023
12 Oct 2023
Historique:
received:
04
09
2023
pmc-release:
12
10
2024
medline:
18
10
2023
pubmed:
18
10
2023
entrez:
18
10
2023
Statut:
epublish
Résumé
Tryptamines, a class of 3-aminoethyl-indoles that activate the serotonin receptor, show potential for novel mental health treatments. The FDA has granted "breakthrough therapy designation" to psilocybin and MDMA for treatment-resistant depression, major depressive disorder, and post-traumatic stress disorder, sparking global research efforts. Various clinical trials are currently investigating the therapeutic value of psilocybin for several mental health disorders. Results thus far indicate significant improvements in patient-reported outcomes via reductions in experiential avoidance. These advancements highlight a promising future for tryptamines in mental health therapy.
Identifiants
pubmed: 37849550
doi: 10.1021/acsmedchemlett.3c00390
pmc: PMC10577885
doi:
Types de publication
Editorial
Langues
eng
Pagination
1331-1333Informations de copyright
Published 2023 by American Chemical Society.
Déclaration de conflit d'intérêts
The author declares no competing financial interest.
Références
Pharmacol Res. 2023 Aug;194:106837
pubmed: 37379962
J Psychopharmacol. 2023 Jul;37(7):649-659
pubmed: 37403379
Psychiatr Clin North Am. 2023 Jun;46(2):291-305
pubmed: 37149346
Int J Ment Health Nurs. 2023 Aug;32(4):1025-1037
pubmed: 36779424
JAMA. 2023 Sep 5;330(9):843-853
pubmed: 37651119
CNS Drugs. 2023 Jul;37(7):571-585
pubmed: 37386328